Breaking News

SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development

Has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development. This first-in-class drug candidate has demonstrated outstanding preclinical efficacy in treating rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), according to the company. Having completed the comprehensive characterization of the molecule, SciRhom will now enter...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters